sellWeak cluster of 210b5-1 plan
David Hallal sold $1.2M of ITOS
director at iTeos Therapeutics, Inc.. 114,682 shares at an average of $10.15, traded Jun 4, 2025, filed Jun 6, 2025.
Warning score
33Value
$1.2M
114,682 shares
Holdings after
0
-300% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$1.2M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-083410, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 4, 2025 | MOption exercise Common Stock10b5-1 | +38,227 | $4.30 | $164k | 38,227 | Jun 6, 2025 |
| Jun 4, 2025 | SOpen-market sale Common Stock10b5-1 | -38,227 | $10.07 | $385k | 0 | Jun 6, 2025 |
| Jun 5, 2025 | MOption exercise Common Stock10b5-1 | +38,227 | $4.30 | $164k | 38,227 | Jun 6, 2025 |
| Jun 5, 2025 | SOpen-market sale Common Stock10b5-1 | -38,227 | $10.15 | $388k | 0 | Jun 6, 2025 |
| Jun 6, 2025 | MOption exercise Common Stock10b5-1 | +38,228 | $4.30 | $164k | 38,228 | Jun 6, 2025 |
| Jun 6, 2025 | SOpen-market sale Common Stock10b5-1 | -38,228 | $10.24 | $391k | 0 | Jun 6, 2025 |
| Jun 4, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,227 | $0.00 | $0 | 76,455 | Jun 6, 2025 |
| Jun 5, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,227 | $0.00 | $0 | 38,228 | Jun 6, 2025 |
| Jun 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,228 | $0.00 | $0 | 0 | Jun 6, 2025 |
Related signals
Other insiders at iTeos Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | iTeos Therapeutics, Inc. | Michel Detheux Chief Executive Officer | $1.0M 104,565 shares | -72% | |
| 43Moderate | iTeos Therapeutics, Inc. | Michel Detheux Chief Executive Officer | $1.6M 156,847 shares | -109% | |
| 42Moderate | ITOSbuy iTeos Therapeutics, Inc. | EcoR1 Capital, LLC owner | $39M 4,958,978 shares | +87% | |
| 53Moderate | iTeos Therapeutics, Inc. | MPM BioVentures 2014, L.P. other | $5.1M 630,191 shares | -23% | |
| 53Moderate | iTeos Therapeutics, Inc. | Ansbert Gadicke other | $8.3M 1,031,931 shares | -23% | |
| 53Moderate | iTeos Therapeutics, Inc. | Mpm Bioventures 2018, L.p. other | $5.1M 630,191 shares | -23% | |
| 31Weak | ITOSbuy iTeos Therapeutics, Inc. | Matthew Gall Chief Financial Officer | $39k 5,000 shares | +8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.